Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 929
Better Engagement, Better Evidence
Writing in The Lancet Global Health, AVAC staffers Stacey Hannah, Jessica Salzwedel, and several co-authors, write about the importance of community stakeholder engagement clearly seen after World Health Organization adoption of new rules requiring clinical trials to improve this kind of coordination.
Topic:
Self-Care Advocacy for HIV and STI Prevention
Self-care is especially critical now, as the new US administration’s sweeping funding cuts and policy shifts threaten to erode support for traditional healthcare services, including HIV and STI programs. By putting testing, prevention, and treatment directly into people’s hands, self-care can help communities maintain vital health services despite reduced funding, limited access to healthcare, and diminished government support.
Prevention Option:
STIWatch Quarterly Newsletter
As many global health fields reassess their reliance on US government funding for research and development, the STI field—already underfunded and reliant on alternate donors—now faces even greater uncertainty. In this newsletter, we share a new STI resource for advocates and highlight the top issues we’re monitoring as events continue to unfold.
The Role of PEPFAR in HIV Prevention
AVAC Senior Program Manager for Policy, John Meade Jr., describes PEPFAR’s historic legacy and strongly argues for its continued importance in the face of attacks by the new US administration. This piece appears in The Broadsheet, the magazine published by the Congressional Black Caucus Health Braintrust.
Impact of PEPFAR’s Stop Work Order on PrEP
The impact of the stop-work order on PrEP is expected to be severe. These slides reflect the results of an analysis drawing on key informant interviews with representatives of Ministries of Health and PrEP implementers between 27 January 2025, when...
Prevention Option:
PxWire Volume 15, Issue No. 1
In this special edition of Px Wire, AVAC is going beyond a quarterly update of biomedical HIV prevention. We look at how the new US Administration’s attack on global health can be expected to devastate HIV prevention, including the capacity to deliver existing PrEP options, the scale up of new PrEP products, and the paralyzing impact on research and development.
Prevention Option:
Global PrEP Uptake and PEPFAR’s Role, 2016-2024
AVAC’s Global PrEP Tracker has documented cumulative PrEP initiations on a quarterly basis for nearly a decade. This graph presents the final data collected while PEPFAR was fully operational—PEPFAR support was responsible for 79% of PrEP uptake globally in the last year and reached 83% by the end of September of 2024. Data on the fourth quarter of 2024 is inaccessible since PEPFAR was taken offline in late January.
Prevention Option:
HIV Incidence, Age 15-49
Looking backward and then into the future, this chart shows actual HIV rates alongside projected rates with and without current prevention strategies (PrEP, VMMC, and free condoms).
Prevention Option:
Where We Are Now with LEN for PrEP
The chaos in foreign assistance programs (including discontinuation of major PrEP programs), cuts in staffing and new demands on donor commitments will make decisions on the procurement of LEN for PrEP more complex and uncertain.
Prevention Option:
Trials & Projects Halted by USAID Funding Suspension
The stop-work orders have disrupted USAID-supported HIV prevention research, halting critical investigations in vaccine and next-generation PrEP strategies.
Prevention Option:
showing 1-10 of 929